Brief: Gensight' Lumevoq Granted 'Promising Innovative Medicine' Designation

Gensight Biologics SA

06/09/2021 06:37

Sept 6 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.PA :
    * UK MHRA GRANTS GENSIGHT BIOLOGICS' LUMEVOQ OPHTHALMIC GENE
THERAPY PROMISING INNOVATIVE MEDICINE DESIGNATION
    * THIS MARKS ANOTHER IMPORTANT MILESTONE IN OUR PREPARATIONS
TO
MAKE LUMEVOQ AVAILABLE TO LHON PATIENTS AS SOON AS POSSIBLE
    * LUMEVOQ IS NOT YET LICENSED IN EU OR IN UK FOR TREATMENT
OF
PATIENTS WITH VISION LOSS DUE TO LEBER HEREDITARY OPTIC
NEUROPATHY (LHON)
    * LUMEVOQ'S MARKETING AUTHORISATION APPLICATION IS CURRENTLY
UNDER
REVIEW BY EUROPEAN MEDICINES AGENCY, WITH A DECISION EXPECTED IN
H1 2022

Source text for Eikon:  ID:nBw7G6kqGa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))